Why GSK's Experimental HIV Drug Could Be a Safer Bet—And a Headache for Gilead – Fortune
Fortune Why GSK’s Experimental HIV Drug Could Be a Safer Bet—And a Headache for GileadFortuneThe two-drug combo could prove less toxic. An experimental therapy from GlaxoSmithKline GSK -0.03% could be just as effective as existing therapies DRUGS?? for HIV/AIDS patients without the corresponding risk of toxic side effects, raising the …GlaxoSmithKline’s New Drug Challenges HIV … Read more